https://www.selleckchem.com/pr....oducts/Nanchangmycin
As treatment interruptions occur during psoriasis management in clinical practice, it is important to know the duration of clinical response after treatment withdrawal. To report time to and predictors of relapse in patients who were tildrakizumab 100 and 200mg responders (≥75% improvement in Psoriasis Area and Severity Index, PASI 75) at week 28 re-randomized to placebo from reSURFACE 1 trial. Post hoc analysis of adult patients with moderate-to-severe plaque psoriasis from a 64-week phase 3 trial. Relapse was primarily defined a
Like
Comment
Share
